A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding.

Tessa C C JaspersKimberly ShudofskyMenno V HuismanKarina MeijerNakisa Khorsand

Published in: Research and practice in thrombosis and haemostasis (2021)

Based on the available evidence with low certainty from observational studies, PCC and andexanet demonstrated a similar, effective hemostasis in the treatment of major bleeding in patients using FXaIs. Compared to PCC, the thromboembolic event rate appeared higher in andexanet-treated patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
atrial fibrillation
prognostic factors
patient reported outcomes
combination therapy